

## **Anti-inflammatory agent 34**

Cat. No.: HY-148456 CAS No.: 867301-81-3 Molecular Formula:  $C_{17}H_{12}N_{2}O_{5}$ Molecular Weight: 324.29 Target: Others Pathway: Others

Storage: Powder -20°C 3 years

> In solvent -80°C 6 months

> > -20°C 1 month

## **SOLVENT & SOLUBILITY**

In Vitro

DMF: 1.85 mg/mL (5.70 mM; ultrasonic and warming and heat to 60°C)

| Preparing<br>Stock Solutions | Solvent Mass<br>Concentration | 1 mg      | 5 mg       | 10 mg      |
|------------------------------|-------------------------------|-----------|------------|------------|
|                              | 1 mM                          | 3.0837 mL | 15.4183 mL | 30.8366 mL |
|                              | 5 mM                          | 0.6167 mL | 3.0837 mL  | 6.1673 mL  |
|                              | 10 mM                         |           |            |            |

Please refer to the solubility information to select the appropriate solvent.

## **BIOLOGICAL ACTIVITY**

| Description | Anti-inflammatory ager   | Anti-inflammatory agent 34 (Compound IVf) is an orally active anti-inflammatory and analgesic agent  [1]. |  |  |
|-------------|--|---|--|--|
| In Vivo     | Anti-inflammatory agent 34 (Compound IVf) (200mg/kg; p.o.; single dose) shows inhibitory activity on carrageen rat paw edema, and shows analgesic activity in mice <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only. |   |  |  |
|             | Animal Model:  | Male albino rats, carrageenan-induced rat paw edema assay $model^{[1]}$                                   |  |  |
|             | Dosage:  | 200 mg/kg   |  |  |
|             | Administration:  | Oral, single dose   |  |  |
|             | Result:  | Showed 55.7 $\pm$ 0.019% inhibition on carrageenan induced rat paw edema at the $3^{rd}$ h.               |  |  |
|             |  |   |  |  |
|             | Animal Model:  | Albino mice, acetic acid induced writhing method $^{\left[1\right]}$                                      |  |  |
|             |  |   |  |  |

| Dosage:         | 200 mg/kg                        |
|-----------------|----------------------------------|
| Administration: | Oral, single dose                |
| Result:         | Showed 48.1% analgesic activity. |

## **REFERENCES**

[1]. Ronad PM, et al. Synthesis and evaluation of anti-inflammatory and analgesic activities of a novel series of substituted-N-(4-methyl-2-oxo-2H-chromen-7-yl) benzamides. Arzneimittelforschung. 2008;58(12):641-6.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: tech@MedChemExpress.com}$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA